ライフサイエンスコーパス: etodolac

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 es the gastrointestinal safety advantages of etodolac.

2 t upper gastrointestinal (CSUGI) events with etodolac.

3 creased event rates with naproxen 2-fold and etodolac 9-fold.

4 associated with a pretreatment regimen with etodolac, a nonsteroidal anti-inflammatory drug (NSAID),

5 R-etodolac also induces apoptosis against primary cells is

6 R-etodolac also inhibits viability of MM cells adherent to

7 mary outcome was the CSUGI event rate of the etodolac and naproxen groups without concomitant low-dos

8 ence in gastrointestinal event rates between etodolac and naproxen when low-dose aspirin was taken co

9 g of a nonsteroidal antiinflammatory drug (R-etodolac), at concentrations that increased apoptosis of

10 Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clin

11 The apoptotic effect of R-etodolac could be controlled by manipulating cellular RX

12 Patients in the etodolac group received two 300 mg capsules 30 minutes p

13 y, neither IL-6 nor IGF-1 protects against R-etodolac-induced cytotoxicity in MM cells.

14 Immunoblot analysis demonstrates that R-etodolac induces apoptosis characterized by caspase-8, -

15 er of the nonsteroidal antiinflammatory drug etodolac inhibited tumor development and metastasis in t

16 Etodolac is a generic COX-2 selective inhibitor that red

17 Etodolac is a generic nonsteroidal anti-inflammatory dru

18 Previous in vitro studies have shown that etodolac is a selective inhibitor of cyclooxygenase (COX

19 g of the nonsteroidal anti-inflammatory drug etodolac, known as SDX-308, and its effects on osteoclas

20 teran patients (5596 patient-years) received etodolac or naproxen during a 3-year period without conc

21 GI events was .78% and .24% for naproxen and etodolac, respectively.

22 GI events was .99% and .24% for naproxen and etodolac, respectively.

23 In this study we report that R-etodolac (SDX-101), at clinically relevant concentration

24 R-etodolac specifically bound recombinant RXRalpha, inhibi

25 the first postsurgical dose was greater for etodolac than for the combination drug.

26 SDX-101 is another structural analog of etodolac that is already used in clinical trials for the

27 Subcytotoxic doses of R-etodolac up-regulate myeloid cell leukemia-1 proapoptoti

28 Compared with naproxen, etodolac was associated with a reduction in upper gastro

29 The combination of R-etodolac with Dex results in a highly synergistic cytoto

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。